JOP20170105B1 - مشتقات بيريدينيل تريازول مستبدلة بأميد واستخدامها - Google Patents

مشتقات بيريدينيل تريازول مستبدلة بأميد واستخدامها

Info

Publication number
JOP20170105B1
JOP20170105B1 JOP/2017/0105A JOP20170105A JOP20170105B1 JO P20170105 B1 JOP20170105 B1 JO P20170105B1 JO P20170105 A JOP20170105 A JO P20170105A JO P20170105 B1 JOP20170105 B1 JO P20170105B1
Authority
JO
Jordan
Prior art keywords
derivatives
pyridinyltriazole
amide
substituted
compounds
Prior art date
Application number
JOP/2017/0105A
Other languages
English (en)
Inventor
Kolkhof Peter
Collin Marie-Pierre
Neubauer Thomas
Furstner Chantal
Pook Elisabeth
Beat Wittwer Matthias
Lustig Klemens
Buchmuller Anja
Tinel Hanna
Drobner Karoline
Mondritzki Thomas
Schirmer Heiko
Kretschmer Axel
Schmeck Carsten
Wasnaire Pierre
Cernecka Hana
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JOP20170105B1 publication Critical patent/JOP20170105B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 5-(carboxamide)-1-pyridinyl-1,2,4-triazole جديدة، وبعمليات لتحضير هذه المركبات، وبتراكيب صيدلية تحتوي على هذه المركبات، وباستخدام هذه المركبات أو التركيبات لمعالجة و/أو الوقاية من الأمراض، تحديدا لمعالجة و/أو الوقاية من الأمراض الكلوية وأمراض القلب والأوعية الدموية.
JOP/2017/0105A 2016-05-03 2017-05-02 مشتقات بيريدينيل تريازول مستبدلة بأميد واستخدامها JOP20170105B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03

Publications (1)

Publication Number Publication Date
JOP20170105B1 true JOP20170105B1 (ar) 2022-03-14

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0105A JOP20170105B1 (ar) 2016-05-03 2017-05-02 مشتقات بيريدينيل تريازول مستبدلة بأميد واستخدامها

Country Status (42)

Country Link
US (4) US9988367B2 (ar)
EP (1) EP3452463B1 (ar)
JP (1) JP6932140B2 (ar)
KR (1) KR20190003655A (ar)
CN (2) CN109415347B (ar)
AR (1) AR108262A1 (ar)
AU (1) AU2017259870B2 (ar)
BR (1) BR112018072542A2 (ar)
CA (1) CA3022749A1 (ar)
CL (1) CL2018003105A1 (ar)
CO (1) CO2018011933A2 (ar)
CR (1) CR20180522A (ar)
CU (1) CU24567B1 (ar)
CY (1) CY1124084T1 (ar)
DK (1) DK3452463T3 (ar)
DO (1) DOP2018000240A (ar)
EA (1) EA035596B1 (ar)
EC (1) ECSP18081881A (ar)
ES (1) ES2866109T3 (ar)
GE (1) GEP20207158B (ar)
HR (1) HRP20210648T1 (ar)
HU (1) HUE053908T2 (ar)
IL (1) IL262557B (ar)
JO (1) JOP20170105B1 (ar)
LT (1) LT3452463T (ar)
MA (1) MA44851B1 (ar)
MX (1) MX2018013335A (ar)
NI (1) NI201800115A (ar)
PE (1) PE20190116A1 (ar)
PH (1) PH12018502268A1 (ar)
PL (1) PL3452463T3 (ar)
PT (1) PT3452463T (ar)
RS (1) RS61771B1 (ar)
SG (1) SG11201809752VA (ar)
SI (1) SI3452463T1 (ar)
SV (1) SV2018005771A (ar)
TN (1) TN2018000368A1 (ar)
TW (1) TWI772295B (ar)
UA (1) UA123791C2 (ar)
UY (1) UY37220A (ar)
WO (1) WO2017191102A1 (ar)
ZA (1) ZA201808131B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452467A1 (de) * 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基***衍生物及其用途
CN109415321B (zh) 2016-05-03 2022-06-17 拜耳制药股份公司 芳族磺酰胺衍生物
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
US10954197B2 (en) * 2017-03-08 2021-03-23 Yogee's Bioinnovations Private Limited Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
CN111033637B (zh) 2017-08-08 2023-12-05 费森尤斯医疗保健控股公司 用于治疗和评估慢性肾脏疾病的进程的***和方法
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
SI3700913T1 (sl) 2017-10-24 2022-02-28 Bayer Aktiengesellschaft Predzdravila derivatov substituiranega triazola in njihove uporabe
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
WO2019081302A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
US11230540B2 (en) 2017-10-24 2022-01-25 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081307A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
WO2019199273A1 (en) * 2018-04-10 2019-10-17 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (en) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Eif4a1 inhibitors with antitumor activity

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1992020662A1 (en) 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
ATE298338T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrin-rezeptor-antagonisten
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
PL345561A1 (en) 1998-07-24 2001-12-17 Bayer Ag Substituted benzoylcyclohexandiones
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
JP3581103B2 (ja) 1999-04-01 2004-10-27 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
ATE556060T1 (de) 2003-03-14 2012-05-15 Merck Sharp & Dohme Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
CA2571907A1 (en) 2003-06-27 2005-01-27 Berglin Corporation Of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
OA13347A (en) * 2003-12-22 2007-04-13 Pfizer Triazole derivatives as vasopressin antagonists.
AU2005231123A1 (en) 2004-03-08 2005-10-20 Wyeth Ion channel modulators
BRPI0508532A (pt) 2004-03-08 2007-08-07 Wyeth Corp moduladores do canal de ìon
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
MY169980A (en) 2010-02-27 2019-06-19 Bayer Ip Gmbh Bisaryl-linked aryltriazolones and their use
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
CA2811192C (en) * 2010-10-01 2018-02-27 Taisho Pharmaceutical Co., Ltd. 1,2,4-triazolone derivative
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JP2015514063A (ja) 2012-03-22 2015-05-18 ビオタ ヨーロッパ リミテッドＢｉｏｔａ Ｅｕｒｏｐｅ Ｌｔｄ 抗菌化合物
SG11201703199UA (en) 2014-11-03 2017-05-30 Bayer Pharma AG Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
EP3452467A1 (de) * 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基***衍生物及其用途

Also Published As

Publication number Publication date
CN113121504A (zh) 2021-07-16
UY37220A (es) 2017-11-30
CN109415347A (zh) 2019-03-01
US10472348B2 (en) 2019-11-12
MA44851A (fr) 2019-03-13
ES2866109T3 (es) 2021-10-19
CR20180522A (es) 2019-01-15
CU20180134A7 (es) 2019-06-04
TW201806941A (zh) 2018-03-01
DOP2018000240A (es) 2019-03-15
EP3452463B1 (en) 2021-03-24
NI201800115A (es) 2019-03-14
PH12018502268A1 (en) 2019-07-15
RS61771B1 (sr) 2021-05-31
PL3452463T3 (pl) 2021-08-09
IL262557B (en) 2022-01-01
PT3452463T (pt) 2021-04-28
CO2018011933A2 (es) 2018-11-22
EA201892505A1 (ru) 2019-04-30
KR20190003655A (ko) 2019-01-09
HUE053908T2 (hu) 2021-07-28
MA44851B1 (fr) 2021-09-30
AR108262A1 (es) 2018-08-01
AU2017259870B2 (en) 2021-07-15
SI3452463T1 (sl) 2021-07-30
CU24567B1 (es) 2022-01-13
WO2017191102A1 (en) 2017-11-09
CN109415347B (zh) 2021-05-07
JP2019514945A (ja) 2019-06-06
US20170320854A1 (en) 2017-11-09
ECSP18081881A (es) 2018-11-30
US11091463B2 (en) 2021-08-17
GEP20207158B (en) 2020-10-12
CA3022749A1 (en) 2017-11-09
UA123791C2 (uk) 2021-06-02
BR112018072542A2 (pt) 2019-03-26
DK3452463T3 (da) 2021-04-26
CL2018003105A1 (es) 2019-02-15
US20180251447A1 (en) 2018-09-06
IL262557A (en) 2018-12-31
MX2018013335A (es) 2019-05-09
SV2018005771A (es) 2019-01-04
TWI772295B (zh) 2022-08-01
US9988367B2 (en) 2018-06-05
CY1124084T1 (el) 2022-05-27
EA035596B1 (ru) 2020-07-14
JP6932140B2 (ja) 2021-09-08
ZA201808131B (en) 2021-05-26
US20190144423A1 (en) 2019-05-16
LT3452463T (lt) 2021-04-26
SG11201809752VA (en) 2018-12-28
PE20190116A1 (es) 2019-01-16
HRP20210648T1 (hr) 2021-05-28
US20200017473A1 (en) 2020-01-16
AU2017259870A1 (en) 2018-11-15
EP3452463A1 (en) 2019-03-13
TN2018000368A1 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
PH12017500802B1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MX2022007607A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
JO3780B1 (ar) مثبطات فيروبورتين جديدة
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2018009870A (es) Inhibidores de taf1 para la terapia del cancer.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
PH12019501999A1 (en) Pyrazole derivatives as bromodomain inhibitors
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена
MX2021000475A (es) Isoxazol como agonista del receptor fxr.
EP3823667A4 (en) METHODS, SYSTEMS AND COMPOSITIONS FOR A NEW USE OF ENTEROBACTIN FOR TREATING IRON DEFICIENCY AND ASSOCIATED ANEMIA